Abstract: Inflammation-mediated bone loss is a major feature of various bone diseases, including chronic periodontitis, rheumatoid arthritis, and osteoarthritis, and is due to an imbalance in bone remodeling that favors resorption. This imbalance is caused by increased cytokine levels in the inflamed tissue. Interleukin (IL)-17 is secreted primarily by activated Th17 cells, and IL-17s and IL-17 receptors play an important role in many autoimmune and inflammatory diseases. The aim of this paper is to review the differences between the indirect effect of IL-17A via osteoblasts and the direct effect of IL-17A on differentiation of osteoclast precursors into osteoclasts and the function of mature osteoclasts in the presence of receptor activator of nuclear factor êâ ligand (RANKL). IL-17A stimulates the production of bone resorption-related inflammatory cytokines through an autocrine mechanism involving celecoxib-blocked prostaglandins (PGs), mainly PGE 2 , in osteoblasts. Furthermore, IL-17A induces the differentiation of osteoclast precursors into osteoclasts and the function of mature osteoclasts via PGE 2 in osteoblasts. On direct effect of IL-17 to osteoclast precursors in the absence of RANKL, IL-17 induces the differentiation as well as indirect effect via osteoblasts. However, the differentiation and function of osteoclasts are suppressed by stimulating osteoclast precursors directly with IL-17A in the presence of RANKL. In conclusion, the effect of IL-17A on RANKL-induced osteoclastogenesis may conflict with the direct action on osteoclast precursors and the indirect action through osteoblasts.
Introduction
Cytokines are important messenger molecules in cell-to-cell communication and are involved in various aspects of the immune system, such as homeostasis maintenance and mediating and resolving pathologic conditions. Inflammation-mediated bone loss is a major feature of various bone diseases, including chronic periodontitis, rheumatoid arthritis, and osteoarthritis, and is due to an imbalance in bone remodeling that favors resorption. This imbalance is caused by increased cytokines and mediators in the inflamed tissue 1) .
Interleukin (IL)-17 is secreted primarily by activated Th17 cells 2, 3) , and IL-17s and IL-17 receptors play an important role in many autoimmune and inflammatory diseases 4) . IL-17 induces the production of extracellular matrix proteins in osteoblasts 5) . On the other hand, several studies have indicated that IL-17 is a proinflammatory cytokine crucial for osteoclastic bone resorption in the presence of osteoblasts [6] [7] [8] . In cartilage, IL-17 activates chondrocytes and macrophages to release degradative enzymes, which probably contributes to the cartilage destruction seen in rheumatoid arthritis at the interface of cartilage 9) . Our recent study showed that IL-17F stimulates cartilage degradation by increasing the expression of collagenases and stromelysin, and decreasing the expression of their inhibitors, type II collagen, and proteoglycans, and the plasminogen/plasmin pathway in chondrocytes 10,11) . IL-17 has been shown to promote osteoclast differentiation indirectly through the induction of IL-1, tumor necrosis factor (TNF)-α, and receptor activator of nuclear factor κβ ligand (RANKL) expression 7, 8, 12) . Regarding the indirect effect of IL-17 on osteoclastogenesis, many studies have reported that IL-17A promotes the differentiation of osteoclast precursors into osteoclasts and the function through osteoblasts [12] [13] [14] [15] [16] [17] [18] . Regarding the direct effect of IL-17, IL-17 was reported to induce the differentiation of human osteoclast precursors 19) and human CD11b-positive cells into osteoclasts in the absence of osteoblasts or exogenous RANKL 20) . In contrast, our report indicates that IL-17A, in the presence of RANKL, suppresses the expression of bone resorption-related proteinases and osteoclast differentiation
The aim of this paper is to review the differences between the indirect effect of IL-17A via osteoblasts and the direct effect of IL-17A via osteoclast precursors on osteoclastogenesis in the presence of RANKL.
Molecules Related to Osteoclastogenesis RANKL, RANK and OPG
RANKL, a member of the TNF family of cytokines, plays a key role in bone resorption. RANKL is expressed by osteoclastogenesis-supporting cells, including synovial fibroblasts, T lymphocytes, and osteoblasts in response to osteoclastogenic factors, such as 1, 25-dihydroxyvitamin D 3 , prostaglandin (PG)E 2 , parathyroid hormone, and several pro-inflammatory cytokines, including IL-1, IL-6, IL-17, and TNF-; this is a crucial determinant of the level of bone resorption in vitro. RANKL functions both as a membrane-anchored molecule and as a soluble molecule [22] [23] [24] [25] . Both forms bind to RANK, the receptor of RANKL, on monocytes, and osteoclastogenesis is induced via intracellular NF B signaling and the activation protein (AP)-1 transcription factor family 26) . RANK is expressed not only in monocytes and osteoclast precursors, but also in mature osteoclasts 27) . .
M-CSF
Osteoblasts produce macrophage colony-stimulating factor (M-CSF), which is required for the survival of cells in the , but exogenous M-CSF induces osteoclast formation in op/op hematopoietic cells 33) , suggesting that the defect in osteoclast recruitment in these animals is not in osteoclast progenitor cells. Additional studies supporting the role of M-CSF in osteoclast recruitment include a report demonstrating that M-CSF is the most effective CSF in stimulating osteoclast formation in normal murine bone marrow 34) and a study showing that M-CSF stimulates bone resorption in an Figure 1 . IL-17A induces the differentiation of RAW264.7 cells into osteoclasts by increasing RANKL and M-CSF production and decreasing OPG production via PGE 2 production in osteoblasts Figure 2 . IL-17A induces production of cathepsin K and MMP-9 in mature osteoclasts through an autocrine mechanism via PGE 2 in osteoblasts organ culture system designed to examine osteoclast formation 35) . On the other hand, M-CSF was reported to be one of the indispensable factors of differentiation from osteoclast precursors to preosteoclasts through the RANK-RANKL signaling system 22) .
Carbonic anhydrase II, cathepsin K and MMP-9
Mature osteoclasts secrete hydrogen ions and proteinases, such as cathepsin K and matrix metalloproteinase (MMP)-9 from a ruffled border that dissolve the inorganic and organic components of bone. Hydrogen ions are produced via carbonic anhydrase II (CA II) from CO 2 and H 2 O in the cytoplasm and are secreted extracellularly by a vacuolar H + -ATPase 36) . This results in the secretion of HCl into the resorptive microenvironment, thus producing a pH equal to approximately 4.5 37) . This acidic milieu first mobilizes bone minerals; subsequently, the demineralized organic component of bone is degraded by lysosomal protease, cathepsin K, and MMP-9 38, 39) . Cathepsin K and MMP-9 are efficient collagenases that cleave both collagen type I and II 40) .
Our previous study indicated that the production of CA II, cathepsin K, and MMP-9 in the murine monocyte/macrophage cell line RAW264.7 is not induced by M-CSF, but by RANKL in the presence of IL-1ß 39) .
Effects of IL-17A on RANKL-Induced Osteoclastogenesis IL-17 family and its receptor
IL-17, initially referred to as CTLA8, is a cloned cytokine produced exclusively by activated Th17 cells 41, 42) . IL-17 shares little or no homology with other interleukins 43) , and at least six members of the family are in the human and mouse genomes: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F 44, 45) . The IL17s are similar in size of 150-180 amino acids and secretory proteins, and display the greatest similarity among their C-terminal 70 amino acids. IL-17A and IL-17F share 44% amino acid identity, whereas other members of the IL-17 family share a more limited 15-27% amino acid identity, suggesting that IL-17A and IL-17F form a distinct subgroup within the IL-17 family 44) . IL-17B through IL-17E are less related, sharing only 16-30% amino acid identity at the primary sequence level, and map to different chromosomes 45) . However, differences in the function of each IL-17 subtype are not clear. IL-17 receptors (IL-17Rs) have been found on several cells and tissues [46] [47] [48] and consist of five subtypes:
IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE [49] [50] [51] [52] . Our report indicated that IL-17R is found in all types in MC3T3-E1 cells from a mouse calvarial cell line 13) . A previous study revealed that IL-17RA and IL-17RC interact together for an optimal response and form a complex to mediate the functions of IL-17A
and IL-17F homodimers, as well as IL-17F/IL-17A heterodimers 53) . In mice, the existence of at least two types of receptors (IL-17RA
and IL-17RC) has been reported 54) . Our study indicated that IL-17RA and IL-17RC expression is highest during the differentiation of RAW264.7 cells into osteoclasts 21) . In this study, IL-17RA expression was found to be induced by the addition of IL-17A, whereas IL-17RC is not affected by IL-17A. In addition, the expression of IL-17RB, IL-17RD, and IL-17RE was not .
Indirect effect of IL-17A on osteoclasts via osteoblasts
Many studies have reported that IL-17A indirectly promotes osteoclastogenesis through osteoblasts [13] [14] [15] [16] [17] [18] . Furthermore, IL-17 was indicated to stimulate RANKL expression in the culture of osteoblasts and bone marrow cells 55) . RANKL expression is also induced by PGE 2 . Our report indicated that IL-17A not only stimulates the expression of inflammatory cytokines such as IL-1 , IL-1ß, IL-8, IL-11, and TNF-via PGE 2 production in osteoblasts, but also induces the differentiation of osteoclast precursors into osteoclasts by increasing the expression of RANKL and M-CSF, and decreasing OPG expression via PGE 2 production in osteoblasts 12,13) (Fig. 1 ). In addition, we indicated that IL-17A
induces the function by increasing cathepsin K and MMP-9 expression of mature osteoclasts via PGE 2 produced by osteoblasts 14) (Fig. 2) .
Direct effect of IL-17A on osteoclasts in the presence of RANKL
Previous studies provide evidence for a direct effect of IL-17 on osteoclast differentiation. In vitro, IL-17 upregulates RANK . In contrast, our previous study indicated that the differentiation of osteoclast precursors into osteoclasts is suppressed at high concentrations of IL-17A in the presence of RANKL (Fig. 4) . Furthermore, IL-17A in the presence of RANKL suppresses the hydrolysis of matrix proteins during bone resorption by decreasing the production of cathepsin K and MMP-9 in mature osteoclasts 21) (Fig. 4) . Thus, the effect of IL-17A in the presence of RANKL may conflict with the direct action on osteoclast precursors and the indirect action through osteoblasts.
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